Revenue: As of FY2026 Q1, the actual value is USD 15.11 M, beating the estimate of USD 13.84 M.

EPS: As of FY2026 Q1, the actual value is USD 0.01.

EBIT: As of FY2026 Q1, the actual value is USD -451 K.

Fennec Pharmaceuticals Inc. operates as a single operating and reportable segment focused on the commercialization of PEDMARK®/PEDMARQSI®.

Segment Revenue

• PEDMARK product sales, net: $15,108 thousand for the three months ended March 31, 2026, compared to $8,751 thousand for the same period in 2025.

Operational Metrics

• Cost of product sales: $570 thousand for the three months ended March 31, 2026, compared to $373 thousand for the same period in 2025.
• Research and development expenses: $49 thousand for the three months ended March 31, 2026, decreased by $45 thousand from $94 thousand for the same period in 2025.
• Selling and marketing expenses: $11,422 thousand for the three months ended March 31, 2026, increased by $8,195 thousand from $3,227 thousand for the same period in 2025.
• General and administrative expenses: $3,186 thousand for the three months ended March 31, 2026, decreased by $2,679 thousand from $5,865 thousand for the same period in 2025.
• Total operating expense: $15,227 thousand for the three months ended March 31, 2026, compared to $9,559 thousand for the same period in 2025.
• Loss from operations: -$119 thousand for the three months ended March 31, 2026, an improvement from -$808 thousand for the same period in 2025.
• Net income/(loss): $201 thousand for the three months ended March 31, 2026, compared to -$1,165 thousand for the same period in 2025.
• Interest expense: -$7 thousand for the three months ended March 31, 2026, decreased by $585 thousand from -$592 thousand for the same period in 2025.
• Interest income: $339 thousand for the three months ended March 31, 2026, increased by $103 thousand from $236 thousand for the same period in 2025.

Cash Flow

• Net cash provided by operating activities: $2,379 thousand for the three months ended March 31, 2026, compared to net cash used in operating activities of -$4,318 thousand for the same period in 2025.
• Net cash provided by investing activities: $0 thousand for both the three months ended March 31, 2026, and 2025.
• Net cash provided by financing activities: $1,012 thousand for the three months ended March 31, 2026, compared to $359 thousand for the same period in 2025.
• Net cash flow: $3,391 thousand increase for the three months ended March 31, 2026, compared to a -$3,959 thousand decrease for the same period in 2025.

Unique Metrics

• Cash and cash equivalents: $40,179 thousand as of March 31, 2026, compared to $36,788 thousand as of December 31, 2025.
• Other current assets: $26,701 thousand as of March 31, 2026, compared to $30,255 thousand as of December 31, 2025.
• Current liabilities: $9,586 thousand as of March 31, 2026, compared to $10,518 thousand as of December 31, 2025.
• Working capital: $57,294 thousand as of March 31, 2026, compared to $56,525 thousand as of December 31, 2025.
• Accumulated deficit: -$229,221 thousand as of March 31, 2026, compared to -$229,422 thousand as of December 31, 2025.
• Total stockholders’ equity: $37,675 thousand as of March 31, 2026, compared to $35,472 thousand as of December 31, 2025.
• Outstanding Shares: As of March 31, 2026, there were 34,541 thousand common shares, 111 thousand warrants, 512 thousand RSU and PSU Awards, and 7,229 thousand stock options outstanding.

Future Outlook and Strategy

Fennec Pharmaceuticals Inc. aims to establish PEDMARK® as the standard of care for cisplatin-induced ototoxicity prevention by increasing awareness and expanding adoption, supported by an expanded sales team and strategic partnerships. The company’s partner, Norgine, is expanding PEDMARQSI® launches in international markets, while Fennec Pharmaceuticals Inc. evaluates opportunities in Japan and supports further studies to characterize PEDMARK®’s use. Fennec Pharmaceuticals Inc. believes existing cash and expected revenues will fund operations for at least the next twelve months, and it continues to pursue strategic alternatives for capital management.